SAVA Nov 2024 27.000 call
| Previous Close | 1.4900 |
| Open | 1.1800 |
| Bid | 0.1900 |
| Ask | 0.5400 |
| Strike | 27.00 |
| Expire Date | 2024-11-08 |
| Day's Range | 0.2300 - 1.2000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 292 |
GlobeNewswireCassava Sciences Reports Q3 2024 Financial and Operating Results
Top-line Data for RETHINK-ALZ 52-week Phase 3 trial Expected Before the End of 2024 $149.0 Million in Cash and Cash Equivalents at September 30, 2024. Expected To Support Operations Into 2026 Conference Webcast Scheduled for Today at 8:30AM ET AUSTIN, Texas, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer’s disease, today reported financial results for the third quarter ended Sep
- GlobeNewswire
Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024
Conference call and webcast to begin at 8:30 AM ETAUSTIN, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it will hold a conference call on Thursday, November 7th at 8:30 a.m. Eastern Time. Event details: Date:Thursday, November 7thTime:8:30 a.m. Eastern TimeAudio Webcast:https://www.CassavaSciences.com/company-presentationsOrAudio Webcast:https://edge.media-server.com/mmc/
